Research
The Division of Pediatric Endocrinology and Diabetes at Stanford is actively involved in clinical research. If you are interested in being contacted about future studies, please complete the Patient List Research Consent Form. Once completed and submitted, the information you provide will be added to our database of potential research participants.
Diabetes Studies
Studies Currently Recruiting
Recruitment Database
This Redcap database - a list of all patients who have indicated interest in being contacted for participation in Stanford Diabetes Research (T1D + T2D). https://redcap.link/t1dt2dresearch.
Information
Age:2– 70 years
Main Eligibility Criteria:
-T1D and T2D
-Any device or mode of insulin delivery
-Currently English only
Contact:
PI: Darrell Wilson, MD
Lead CRC: Sarah Hanes sjhanes@stanford.edu
Pathway to Prevention (TrialNet)
Phase 1 Screening: testing for presence of diabetes related autoantibodies. Phase 2 Monitoring: Annual retesting if one autoantibody is positive; Semi-annual study visits if 2 or more autoantibodies are positive. Potential entry into T1D prevention studies.
Information
Age:2.5 – 45 years
Main Eligibility Criteria:
-Relatives of patients with T1D
-English and Spanish Speakers
-Please discuss subjects with PI first
Duration Time for Pt in Study: Screening: 1 visit Positive autoantibodies
Contact:
PI: Priya Prahalad, MD, PhD & Darrell Wilson, MD
Lead CRC: Alondra Loyola aloyola1@stanford.edu
Low Dose ATG
A 2:1 randomized clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D. Subjects receive either ATG or placebo in 2 infusions (overnight hospital stay), then come for F/U.
Information
Age:12-35 years
Main Eligibility Criteria:
-Stage 2 at Risk Subjects
-Must have at least two of the high-risk markers
-Abnormal glucose tolerance
Duration Time for Pt in Study: At least 24 Months
Contact:
PI: Priya Prahalad, MD, PhD & Darrell Wilson, MD
Lead CRC:Trudy Esrey, RD, CDE; tesrey@stanford.edu
DiabetesWise for Exercise
The Aim of this project is to make it easier for people with diabetes and their healthcare providers (HCPs) to access and utilize vetted, helpful exercise and physical activity (PA) guidance.
Information
Age:10 – 80 years
Main Eligibility Criteria:
-T1D and T2D
-English or Spanish Speaking
-Any Insurance
-On any Diabetes Technology
Duration Time for Pt in Study: 6 months
Contact:
PI: Dessi Zaharieva
Lead Project Manager: Lauren Figg lefigg@stanford.edu
SPEED PA
Participants who attend the SPEED class will be given the opportunity to join the tracker study to wear a physical activity tracker to observe how exercise impacts blood glucose.
Information
Age:11-21 years
Main Eligibility Criteria:
-T1D only
-Must complete SPEED class prior to enrollment
Duration Time for Pt in Study: At least 20 Months
Contact:
PI: Dessi Zaharieva, PhD
Lead CRC: Ilenia Balistreri illiee@stanford.edu
JAKPOT TN31
Trial testing 2 JAK inhibitors, abrocitinib and ritlecitinib in new onset T1D participants. Randomized in a 1:1:1 allocation with placebo as 3rd arm. 12 months of active treatment (daily oral medication) with drug or placebo, then 12 months of F/U.
Information
Age:12 – 35 years
Main Eligibility Criteria:
-New Onset T1D within100 days of diagnosis
-English or Spanish Speaking
-Compensation for study-related travel provided.
-Duration Time for Pt in Study: 24 Months: 12 months of
treatment; 12 months of follow up
Contact:
PI: Priya Prahalad, MD, PhD and Darrell Wilson, MD
Lead CRC:Trudy Esrey tesrey@stanford.edu
DIAGNODE-3 STUDY
Trial testing an investigational drug, Diamyd® (rhGAD65), to determine its ability to preserve the body’s insulin-producing capacity by halting or delaying the autoimmune attack on the beta cells. Randomized 2:1 study agent: placebo. Screening visits followed by 3 monthly injections of drug or placebo, then 22 months of F/U.
Information
Age:12 – 28 years
Main Eligibility Criteria:
-New Onset T1D within 6 months of diagnosis
-Presence of HLA DR3-DQ2 haplotype (you will be tested for this)
-English or Spanish Speaking
-Compensation for study-related travel provided.
Duration Time for Pt in Study: 26 months: 3 Screening run-in visits, 3 injections over 2 months, 22 months of follow up visits.
Contact:
PI: Priya Prahalad, MD, PhD and Darrell Wilson, MD
Lead CRC:Trudy Esrey tesrey@stanford.edu
PBD Diet for T2D Youth
The Plant Based Diets (PBDs) will be explored in the peds population. Youth with prediabetes or T2D will take part in a study to see the role of PBDs in disease management. Labs, CGM and Garmin Watch data will be obtained at the end of the 1-month diet.
Information
Age:10– 22 years
Main Eligibility Criteria:
-T2D for more than 3 months
Contact:
PI: Ananta Addala, DO, MPH
Lead CRC: Daniel Garfias Silva dgarfias@stanford.edu
Stigma in Pediatric T2D
Families engage in surveys/focus groups. Child's medical chart will be used to understand medical trends --blood pressure, HbA1c, cholesterol. This study seeks to identify and understand the experience of stigma related to T2D.
Information
Age:13 – 21 years
Main Eligibility Criteria:
-T2D
-Any Insurance
-English or Spanish Speaking
Duration Time for Pt in Study: 20 months
Contact:
PI: Ananta Addala, DO, MPH
Lead CRC: Daniel Garfias Silva dgarfias@stanford.edu
Pre-Pro Insulin (Bio-Banking)
We hope to learn why some individuals develop T1D while others don’t by looking at pre-proinsulin and the immune response.
Information
Age:2 – 70 years
Main Eligibility Criteria:
-T1D, T2D, Family Member of T1D, Controls
Duration Time: 1 Blood Draw unless wanting to give blood again
Contact:
PI: Kent Jensen, PhD; Everett Meyer, MD, PhD
Lead CRC: Abby Twoy atwoy@stanford.edu
ENABLE
This study looks at blood samples from a finger stick collected by patients, a finger stick collected by a healthcare professional, and a blood sample collected by venipuncture will yield similar results in detecting autoantibodies in terms of accuracy and sensitivity.
Information
Age: 1 – 80 years
Main Eligibility Criteria:
-T1D less than 10 days after first insulin injections
Duration Time: 1 day only – 2 finger pricks, 1 blood draw, and 1 survey
Contact:
PI: Priya Prahalad, MD, PhD
Lead CRC: Rachel Tam ratam@stanford.edu
Other Endocrine Studies
PWS-Open Label Continuation phase of Carbetocin Nasal Spray
A Long-term, Open-label Extension Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Information
Age: 5-30 yrs
Main Eligibility Criteria:
-English and Spanish speaking
Duration Time: 3 years
Contact:
PI: Diane Stafford, MD
Lead CRC: Alondra Loyola aloyola1@stanford.edu
PWS-Non-Invasive Vagus Nerve Stimulation
A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS (VNS4PWS) in Prader-Willi Syndrome
Information
Age: 10-40 yrs
Main Eligibility Criteria:
-English speaking
Duration Time: 2 years in length including the Open Label Extension
Contact:
PI: Diane Stafford, MD
Lead CRC: Alondra Loyola aloyola1@stanford.edu
Mission Statement
Our mission is to innovate basic, translational, and clincial research in endocrinology and diabetes grounded in the principles of excellence and equity to advance scientific knowledge and improve the lives of all.
Stanford Diabetes Research Center
The SDRC promotes the teaching and training goals of Stanford University by training the next generation of investigators and leaders of diabetes research and care.
Basic Research
The aim of our basic science program is to elucidate the role of the endocrine system in both health and the development of diseases. Through this work, we hope to increase our understanding of the important physiological processes that are controlled by hormones and how alterations in hormone levels perturb the body’s homeostasis and cause disease in people. Our goal is to apply discoveries we make in the laboratory toward the development of novel therapeutics for a variety of illnesses that affect children.
You can read more about the work of faculty member Anna Gloyn and her team.
Research Database
Join our database to receive study recruitment emails. Click the button below.